The paradoxical effect of bevacizumab in the therapy of malignant gliomas

Neurology

Volumn 76, Issue 1, 2011, Pages 87-93

  Thompson, Eric M ^a   Neuwelt, Edward A ^a,b,d   Frenkel, Eugene P ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DEXAMETHASONE; GADODIAMIDE; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER INVASION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GLIOBLASTOMA; HUMAN; LUNG EMBOLISM; NONHUMAN; OXYGEN TRANSPORT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TISSUE PRESSURE; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 78751620483     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318204a3af     Document Type: Article

References (52)

1. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-345.
2. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-1260.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
5. Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 2008;109:268-272.
6. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267-2273.
7. Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 2008;89:113-118.
8. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-180.
9. Rich JN, Desjardins A, Sathornsumetee S, et al. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma. J Clin Oncol (Meeting Abstracts) 2008;26:2022.
10. Thompson EM, Dosa E, Kreamer DF, Neuwelt E. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 2010;67:87-93.
11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
12. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
13. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
14. Kreisl TN, Kim L, Moore K, et al. Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
15. Lamborn KR, Yung WK, Chang SM, et al. Progressionfree survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol 2008;10:162-170.
16. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-2578.
17. Pazdur R. National Cancer Institute: FDA approval for bevacizumab. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed July 19, 2009.
18. Desjardins A, Reardon DA, Peters K, et al. Bevacizumab (BV) in combination to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM): a phase 2 trial. Presented at the annual meeting of the Society for Neuro-Oncology; October 22-24, 2009; New Orleans, LA.
19. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-1380.
20. RTOG. Phase III double-blind placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. Available at: www.rtog.org/members/protocols/ 0825/0825.pdf. Accessed April 19, 2010.
21. Chinot O, de la Motte Rouge T, Moore N, Zeaiter A. Addition of bevacizumab to the multi-modality standard of care in patients with newly diagnosed glioblastoma: a phase III trial. Eur J Cancer Suppl 2009;7:497.
22. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001;74:7-25.
23. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005;27:371-377.
24. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-591.
25. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(suppl 3): 11):11-16.
26. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumabinduced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-3950.
27. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008;7:71-78.
28. Leenders WP, Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004;10:6222-6230.
29. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008;8:592-603.
30. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 2009;15:7092-7098.
31. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncol 2010;12:233-242.
32. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-336.
33. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-1206.
34. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
35. Iwama T, Yamada H, Sakai N, et al. Correlation between magnetic resonance imaging and histopathology of intracranial glioma. Neurol Res 1991;13:48-54.
36. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008;88:339-347.
37. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787.
38. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009;29:853-860.
39. NCBI. Gadodiamide: Compound Summary (CID 24838310). Available at: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=197004&viewopt= PubChem. Accessed April 19, 2010.
40. NCBI. Irinotecan: compound summary (CID 104842). Available at: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=104842&loc=ec-rcs. Accessed June 25, 2010.
41. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010;30:15-35.
42. Cloughesy T, Vredenburgh JJ, Day BM, et al. Updated safety and survival in patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. Am Soc Clin Oncol 2010;28:15s.
43. Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro-Oncol 2009;11:142-150.
44. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-461.
45. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-2197.
46. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
47. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
48. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys Epub 2010 April 13.
49. Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005;23:4127-4136.
50. Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Curr Opin Neurol 2008;21:717-719.
51. European Medicines Agency. Refusal Assessment Report for Avastin. London: European Medicines Agency; 2010.
52. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrastenhanced perfusion MR imaging. Radiology 2008;247:490-498.